Lilly to market euro bonds as low rates lure U.S. firms
The drugmaker plans to sell 2.1 billion euros ($2.3 billion) of securities in three parts, according to a person familiar with the matter who asked not to be identified.
Eli Lilly and Co.
Articles
Lilly pledges $60M to German firm to form research partnership
In a bid to get into the white-hot market for drugs that use the body’s immune system, Eli Lilly and Co. will spend $60 million to form a research partnership with Germany-based BioNTech.
Former Lilly partner set to pay $2.3B to settle Actos cases
Takeda Pharmaceutical Co. executives have agreed to pay more than $2.3 billion to resolve lawsuits accusing the company of hiding its Actos diabetes medicine’s cancer risks, three people familiar with the accord said.
Princeton loses appeal in case sparked by Lilly drug loyalties
Four residents of the town of Princeton sued to revoke the university’s tax exemption, in part because it shares royalties with faculty, mostly from a patent that Indianapolis-based Eli Lilly and Co. turned into the cancer drug Alimta.
Lilly rethinks its philanthropy strategy
“Shared value” approach directs resources to help people in ways that could build the drugmaker’s business.
Alzheimer’s debate revived by new Mayo Clinic study
New research from the Mayo Clinic is bringing back a long-running debate over whether drug companies like Eli Lilly and Biogen are focusing on the right target in developing therapies to treat the disease.
How ‘losing’ the headquarters of two promising drug firms could help Indiana
The fact that Assembly Biosciences Inc. and AgeneBio now list New York and Baltimore, respectively, as their headquarters cities doesn’t hurt Indiana and could help the state, says David Johnson, CEO of BioCrossroads.
Pay dips, but pension values soar for Lilly’s top execs
The top five executives at Eli Lilly and Co. took home 5 percent to 10 percent less in cash, stock and perks last year than the year before, according to a Monday securities filing.
Potential Alzheimer’s drug further backs protein hypothesis
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
Hoosier docs enjoy more than $40M a year from drug, device firms
New research shows patients lose trust and confidence in doctors that take money for travel, but like it when their doctors are paid as consultants during the development of new products.
Lilly joins $100M global Alzheimer’s venture fund
Major drugmakers—including Indianapolis-based Eli Lilly and Co.—the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or cure.
Sponsorship of diabetic NASCAR driver may help Lilly regain market share
21-year-old Ryan Reed stunned racing gurus on Feb. 21 by winning his first NASCAR race on stock-car racing’s most hallowed grounds. He did it with a wireless device attached to his stomach feeding a constant stream of data to a dashboard-mounted glucose monitor.
Warnings ordered on testosterone drugs like Lilly’s Axiron
Makers of testosterone drugs must change the products’ labels to clarify that they are approved for only certain disorders, not to help men deal with aging, U.S. regulators said.
Killing obesity without coercion
Top-down culture change only works in North Korea, says the head of a group of local CEOs that is working broadly and subtly, not tyrannically, to improve Indy’s culture of eating and exercising.
Lilly to introduce Lantus copy in Europe after patent expires
Paris-based drugmaker Sanofi had revenue of $8.4 billion from Lantus last year. It lost U.S. patent protection this month and will lose exclusive rights in Europe in May.
Lilly to delay U.S., EU approval of basal insulin
Although the experimental diabetes drug is in final-stage testing and showing promising results, Lilly wants to better understand its effect on liver fat.
Feds finally end probe into Lilly bribery allegations
The U.S. Department of Justice told Lilly last month its investigation was over—more than a year after the drugmaker paid $29 million to the SEC to settle related bribery allegations.
Former Lilly partner ordered to pay $2.3M to Actos user
Takeda Pharmaceutical Co. was ordered by a jury Thursday to pay more than $2.3 million in damages to a former teacher who blamed the company’s Actos diabetes drug for causing his bladder cancer.
How Eli Lilly CEO Lechleiter pulled company out of long slide
After weathering a barrage of patent expirations, the pharmaceutical giant has restocked its pipeline and is positioned to grow.
Cuban immigrant gets 6 years for theft of Lilly drugs
A Cuban immigrant was sentenced Wednesday to more than six years in prison for his role in the 2010 heist of a Connecticut warehouse in which the robbers filled a tractor-trailer with more than $50 million worth of Eli Lilly and Co. pharmaceuticals.